HC Wainwright Reiterates Buy Rating for Genfit (NASDAQ:GNFT)

Genfit (NASDAQ:GNFT)‘s stock had its “buy” rating restated by equities researchers at HC Wainwright in a research note issued to investors on Friday, Benzinga reports. They currently have a $13.00 target price on the stock. HC Wainwright’s price objective would suggest a potential upside of 168.60% from the company’s current price.

Genfit Price Performance

Shares of NASDAQ:GNFT opened at $4.84 on Friday. The company has a 50 day moving average of $4.23 and a 200-day moving average of $4.05. Genfit has a twelve month low of $2.89 and a twelve month high of $6.05. The company has a quick ratio of 2.94, a current ratio of 2.94 and a debt-to-equity ratio of 0.92.

Institutional Trading of Genfit

A hedge fund recently raised its stake in Genfit stock. Optiver Holding B.V. boosted its holdings in shares of Genfit S.A. (NASDAQ:GNFT) by 2,229.2% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 82,359 shares of the company’s stock after purchasing an additional 78,823 shares during the period. Optiver Holding B.V. owned approximately 0.17% of Genfit worth $315,000 at the end of the most recent quarter. Institutional investors own 2.24% of the company’s stock.

About Genfit

Genfit SA, a late-stage biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases. The company develops Elafibranor, which is in Phase III clinical trial to treat patients with primary biliary cholangitis. It also engages in the development of NIS4 technology for the diagnosis of nonalcoholic steatohepatitis (NASH) and fibrosis; VS-01 for the treatment of Urea Cycle Disorder (UCD) and Organic Acidemia Disorder (OAD); GNS561, which is in Phase 1b/2a trial to treat patients with cholangiocarcinoma (CCA); VS-01-ACLF and Nitazoxanide (NTZ), which is in Phase 1 trial to treat acute-on-chronic liver failure, as well as VS-02-HE, which is in preclinical trial for the treatment of Reduction of Hyperammonemia and the Stabilization of Blood Ammonia; CML-022; SRT-015, an ASK1 inhibitor targets the inhibition of cellular apoptosis, inflammation, and fibrosis.